- Home
- AIM
as 05-20-2024 4:00pm EST
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
| Founded: | 1966 | Country: | United States |
| Employees: | N/A | City: | OCALA |
| Market Cap: | 20.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 233.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.32 - $0.75 | Next Earning Date: | 05-16-2024 |
| Revenue: | $193,000 | Revenue Growth: | 23.72% |
| Revenue Growth (this year): | -30% | Revenue Growth (next year): | 1735.93% |
Share on Social Networks:
Stock Insider Trading Activity of AIM ImmunoTech Inc. (AIM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rodino Peter W III | AIM | COO, Secretary, Gen. Counsel | May 6 '24 | Buy | $0.41 | 30,865 | $12,500.33 | 212,583 | SEC Form 4 |
| Equels Thomas K | AIM | CEO & President | May 6 '24 | Buy | $0.41 | 61,729 | $25,000.25 | 778,184 | SEC Form 4 |
| BRYAN NANCY | AIM | Director | Mar 21 '24 | Buy | $0.39 | 38,462 | $15,000.18 | 38,462 | SEC Form 4 |
| Rodino Peter W III | AIM | COO, Secretary, Gen. Counsel | Mar 15 '24 | Buy | $0.33 | 37,879 | $12,500.07 | 181,718 | SEC Form 4 |
| Equels Thomas K | AIM | CEO & President | Mar 15 '24 | Buy | $0.33 | 75,758 | $25,000.14 | 716,455 | SEC Form 4 |
Latest AIM ImmunoTech Inc. News
AIM Breaking Stock News: Dive into AIM Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 hours ago
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
GlobeNewswire
4 days ago
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
Argus Research
5 days ago
Daily – Vickers Top Insider Picks for 05/15/2024
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 05/13/2024
Argus Research
10 days ago
Daily – Vickers Top Insider Picks for 05/10/2024
GlobeNewswire
11 days ago
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
GlobeNewswire
14 days ago
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
GlobeNewswire
21 days ago